Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | -6.25% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.51 | N/A | -6.25% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution about the current market conditions. They reiterated their focus on long-term objectives despite recent setbacks.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing commitment to their strategic goals.
No specific updates were provided regarding future product launches.
Alnylam Pharmaceuticals reported a loss that was slightly worse than expected, which typically raises concerns among investors. However, the stock rose by 1.39%, likely due to broader market trends or investor optimism about future developments. The lack of revenue data and guidance leaves some uncertainty about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMKOR TECHNOLOGY INC
Feb 10, 2014